Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) is expected to release its earnings data before the market opens on Wednesday, May 14th. Analysts expect Eupraxia Pharmaceuticals to post earnings of ($0.19) per share for the quarter.
Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.02). On average, analysts expect Eupraxia Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Eupraxia Pharmaceuticals Stock Performance
Eupraxia Pharmaceuticals stock remained flat at $3.80 during midday trading on Friday. 3,270 shares of the company's stock traded hands, compared to its average volume of 14,648. The business has a 50-day moving average price of $3.62 and a 200 day moving average price of $3.34. Eupraxia Pharmaceuticals has a 52 week low of $2.20 and a 52 week high of $4.48. The stock has a market cap of $136.23 million and a PE ratio of -5.28.
Analyst Ratings Changes
Separately, Craig Hallum began coverage on Eupraxia Pharmaceuticals in a report on Friday, February 21st. They issued a "buy" rating and a $12.00 price objective on the stock.
Read Our Latest Research Report on EPRX
About Eupraxia Pharmaceuticals
(
Get Free Report)
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.
See Also
Before you consider Eupraxia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eupraxia Pharmaceuticals wasn't on the list.
While Eupraxia Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
